Access cutting-edge merkel cell carcinoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access merkel cell carcinoma specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related merkel cell carcinoma treatment provided free
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor c
Sponsor: National Cancer Institute (NCI)
Check if you qualify for this merkel cell carcinoma clinical trial in Palo Alto, CA
If you're searching for merkel cell carcinoma treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced merkel cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.